TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Near Add Your Location
Sorting 34 by
Hematology Oncology Associates of Fredericksburg Inc
Fredericksburg, VA
- Not yet accepting
Baptist Cancer Center Memphis
Mempis, TN
- Accepting patients
Sanford Cancer Center
Sioux Falls, SD
- Not yet accepting
New Jersey Cancer Care
Belleville, NJ
- Not yet accepting
Lumi Research
Kingwood, TX
- Accepting patients
Mosaic Life Care
Saint Joseph, MO
- Not yet accepting
Cancer Specialists of North Florida - Riverside
Jacksonville, FL
- Not yet accepting
- Accepting patients
- Accepting patients
Avera Cancer Institute - Sioux Falls
Sioux Falls, SD
- Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.